Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Retained Earnings: 2012-2024

Historic Retained Earnings for Agios Pharmaceuticals (AGIO) over the last 13 years, with Dec 2024 value amounting to -$148.9 million.

  • Agios Pharmaceuticals' Retained Earnings fell 765.76% to -$453.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$453.7 million, marking a year-over-year decrease of 765.76%. This contributed to the annual value of -$148.9 million for FY2024, which is 81.90% up from last year.
  • According to the latest figures from FY2024, Agios Pharmaceuticals' Retained Earnings is -$148.9 million, which was up 81.90% from -$822.6 million recorded in FY2023.
  • Agios Pharmaceuticals' Retained Earnings' 5-year high stood at -$148.9 million during FY2024, with a 5-year trough of -$1.8 billion in FY2020.
  • Moreover, its 3-year median value for Retained Earnings was -$470.6 million (2022), whereas its average is -$480.7 million.
  • In the last 5 years, Agios Pharmaceuticals' Retained Earnings soared by 87.05% in 2021 and then crashed by 97.09% in 2022.
  • Yearly analysis of 5 years shows Agios Pharmaceuticals' Retained Earnings stood at -$1.8 billion in 2020, then skyrocketed by 87.05% to -$238.8 million in 2021, then slumped by 97.09% to -$470.6 million in 2022, then crashed by 74.82% to -$822.6 million in 2023, then skyrocketed by 81.90% to -$148.9 million in 2024.